ICTUImperial Clinical Trials Unit

Welcome to Imperial Clinical Trials Unit (ICTU)

This website is intended for commercial trial sponsors engaged in the area of pharmaceuticals, medical devices or diagnostic devices

Clinical Trials Search


CurrentAll Trials

CHERUB 003 - 301

Trial Details

  • Trial statusClosed
  • Study email contactcherub@imperial.ac.uk
  • Chief InvestigatorDr Sarah Fidler
  • Project managern/a - study closed
  • SponsorImperial College, London
  • Phasen/a

Prospective observational study of HIV positive individuals on suppressive HAART with malignancy undergoing chemotherapy

Design and Objective

Although HAART has made a great improvement to the health and lives of all people living with HIV, HAART cannot be stopped because it is not able to ‘cure’ or eliminate the HIV virus. There is some laboratory evidence that treatments for certain types of cancer can have an effect on latent virus in the body. We will therefore study levels of latent virus in HIV patients with cancer before and after cancer treatment.

Key inclusion criteria

• Aged ≥ 18 years and able to give written informed consent • Aware of HIV status and the diagnosis of malignancy • Plasma viral load of < 50 HIV1 RNA copies/ml (on suppressive HAART) at enrolment • Be designated to receive cytotoxic chemotherapy including: RCHOP, ABVD, Caelyx, Daunoxome or Paclitaxel

Study Disclaimer Statement